Content discovery platform

Alltrna Appoints Caroline Kӧhrer, Ph.D., Vice President, Discovery Platform

Retrieved on: 
Monday, October 17, 2022
Rubius, Infection, Ribosome, Microbiology, Disease, Therapy, Content discovery platform, Technology, RNA transfection, Growth, Essential amino acid, SANA, NASDAQ, Biology, RNA, Research, Publication, University of Innsbruck, PNAS, Multimedia, Science, Investment, Flagship Pioneering, Protein engineering, University, MRNA, Health, CEO, Ecosystem, Flagship, Cell Metabolism, Springer, David Berry (inventor), Nature Communications, Massachusetts Institute of Technology, Autoimmunity, COVID-19, Language, Leadership, Vaccine, Pharmaceutical industry, Medical device, Fine chemical, Moderna

CAMBRIDGE, Mass., Oct. 17, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Caroline Kӧhrer, Ph.D., as Vice President, Discovery Platform. 

Key Points: 
  • Under her leadership, Moderna expanded the mechanistic understanding of mRNA design principles underlying current and future mRNA therapeutics, including Moderna's Spikevax mRNA vaccine for COVID-19.
  • "We are excited to have Caroline join us as we boldly establish a first-in-field platform to advance tRNA as a new modality with exceptional and unique therapeutic potential."
  • The company's platform incorporates AI/ML tools to learn the tRNA language and deliver diverse programmable molecules with broad therapeutic potential.
  • Alltrna has an unprecedented opportunity to advance a single tRNA medicine to unify treatment across a wide range of diseases with the same underlying genetic mutation.

Model Medicines Announces Launch of Oncology Programs with Multiple AI-Discovered Compounds Demonstrating Drug-Like Activity for Two High Value, Difficult to Drug, Oncogenic and Epigenetic Targets

Retrieved on: 
Tuesday, October 4, 2022
Association, AXL, Entrepreneurship, Doctor of Philosophy, Engineering, Disease, Icahn School of Medicine at Mount Sinai, Biology, Drug development, Industry, Drug discovery, BRD4, CEO, Stomach, Multimedia, FDA, Infection, Mount Sinai, Content discovery platform, Artificial intelligence, CA, Machine learning, Scripps Research, LA, Lists of diseases, Therapy, Company, Pharmaceutical industry

Model Medicine's GalileoPlatform has discovered multiple chemotypes novel to AXL and BRD4 that demonstrate nanomolar or low micromolar activity in in vitro validation studies.

Key Points: 
  • Model Medicine's GalileoPlatform has discovered multiple chemotypes novel to AXL and BRD4 that demonstrate nanomolar or low micromolar activity in in vitro validation studies.
  • LA JOLLA, Calif., Oct. 4, 2022 /PRNewswire/ -- Model Medicines , a pharmatech company working to transform the drug discovery and development industry using artificial intelligence (AI), today announced the launch of its oncology programs.
  • Model Medicines announces the launch of their oncology programs with multiple AI-discovered compounds for two targets.
  • Model Medicines' discovery of multiple new chemotypes with activity against these high value targets represents a significant breakthrough.

Candel Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for CAN-2409 in Glioma

Retrieved on: 
Thursday, September 15, 2022
Herpes simplex virus, CADL, FDA, MD, COMP, Brain, Food, Virus, European Medicines Agency, European Commission, Company, Population, Pancreatic cancer, Private Securities Litigation Reform Act, Therapy, Valaciclovir, Person, Neoplasm, Patient, Clinical trial, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cancer, Disease, CEO, Technology, Nasdaq, Doctor of Philosophy, Immunogenic cell death, HSV, Lung, Tumor microenvironment, Committee, Large-cell lung carcinoma, Prostate cancer, Royal commission, SEC, Union, Mortality, Content discovery platform, Marketing, GLOBE, EMA, Pharmaceutical industry, Vaccine, Fellow of the Academy of Medical Sciences, EU, Candel, Glioma

The orphan drug designation follows the U.S. Food and Drug Administration (FDA) fast track designation, which was granted in June 2021, for CAN-2409 in combination with valacyclovir following standard of care treatment in newly diagnosed high-grade glioma.

Key Points: 
  • The orphan drug designation follows the U.S. Food and Drug Administration (FDA) fast track designation, which was granted in June 2021, for CAN-2409 in combination with valacyclovir following standard of care treatment in newly diagnosed high-grade glioma.
  • Paul Peter Tak, MD, PhD, FMedSci, President and CEO of Candel, said, "Glioma, while mercifully rare, is a devastating disease with significant morbidity and mortality.
  • The EMA's orphan drug designation recognizes the high unmet need and the potential of CAN-2409 in this patient population.
  • Orphan drug designation in the European Union (EU) is granted by the European Commission based on a positive opinion issued by the EMA COMP.

Ideon Technologies Raises US$16M Series A to Accelerate Supernova-Charged Subsurface Imaging Solution for Critical Mineral Discovery

Retrieved on: 
Tuesday, September 13, 2022
Technology, Research, Satellite, Software, Mining, Minerals, Hardware, Science, Artificial Intelligence, Natural Resources, BHP, World Bank Group, Engineering, 3D, Risk, Entrepreneurship, Knowledge, Playground, Partnership, Industry, Mining, Technology, Content discovery platform, Mineral, Automation, CEO, Playground Global, Cave, Magnetometer, Explosion, Solution, Uncertainty, Map, Science, Artificial intelligence, General partnership, Multimedia, Discovery, Rare-earth element, Uranium, Medical imaging, Space Runaway Ideon, Technology, Research, Satellite, Software, Mining, Minerals, Hardware, Science, Artificial Intelligence, Natural Resources

Ideon Technologies, a global pioneer in high-resolution subsurface imaging for the mining industry, announced it closed a US$16M Series A funding round, led by Playground Global.

Key Points: 
  • Ideon Technologies, a global pioneer in high-resolution subsurface imaging for the mining industry, announced it closed a US$16M Series A funding round, led by Playground Global.
  • The Discovery Platform integrates proprietary muon detectors, imaging systems, inversion technologies, and artificial intelligence to deliver exceptional locational accuracy with higher spatial resolution than any other existing technique.
  • Ideon maps the intensity of muons underground and constructs detailed 3D density profiles of underground anomalies such as mineral and metal deposits, air voids, caves, and other structures.
  • Ideon is already working with some of the worlds largest, most innovative mining companies and critical mineral suppliers, including BHP, Glencore, and Vale.

Candel Therapeutics Announces Two Executive Leadership Appointments

Retrieved on: 
Wednesday, September 7, 2022
CEO, Technology, Virus, GSK, CADL, Infection, Internal medicine, LTD, Content discovery platform, Certified Public Accountant, GLOBE, Company, Smallpox, Patient, Deloitte, Cancer, University of Washington Department of Bioengineering, Seattle Cancer Care Alliance, Board, Genzyme, Duke University, SEC, CFO, GlaxoSmithKline, Nasdaq, MS, Treasurer, New England Baptist Hospital, Therapy, Immunogenic cell death, Disease, Acer, Commonwealth, HSV, Faculty, HIV, ViiV Healthcare, Fred Hutchinson Cancer Research Center, Private Securities Litigation Reform Act, CMO, University, IPO, HIV/AIDS, Epidemiology, Family, Pharmaceutical industry, Management, Vaccine, Fellow of the Academy of Medical Sciences, Akebia, Candel, MD, Doctor of Philosophy, Boston College

Mr. Amello and Dr. Nichols together bring over five decades of biopharmaceutical experience to Candel.

Key Points: 
  • Mr. Amello and Dr. Nichols together bring over five decades of biopharmaceutical experience to Candel.
  • He was instrumental in shaping the Company as we executed our IPO in 2021 and has continued to provide valuable strategic guidance to Candel.
  • On behalf of the board, the leadership team and all of the Candel employees, we wish him well.
  • Mr. Amello comes to Candel from Saniona AB, a rare disease biotech company where he served as CFO.

Candel Therapeutics Upcoming Investor Conference Participation

Retrieved on: 
Tuesday, September 6, 2022
Technology, Cancer, Immunogenic cell death, News, Virus, HSV, SEC, Content discovery platform, Company, Form, Investor, Webcast, Private Securities Litigation Reform Act, Patient, Vaccine, Candel

A live webcast of the H.C. Wainwright company presentation is available here and can be accessed by visiting the Investors section of Candel Therapeutics website at www.ir.candeltx.com and selectingEvents and Presentationsunder the News & Events tab.

Key Points: 
  • A live webcast of the H.C. Wainwright company presentation is available here and can be accessed by visiting the Investors section of Candel Therapeutics website at www.ir.candeltx.com and selectingEvents and Presentationsunder the News & Events tab.
  • A replay of the webcast will be archived for up to 90 days following the presentation date.
  • CAN-2409 is the lead product candidatefrom the adenovirus platform and CAN-3110 is the lead product candidate from the HSV platform.
  • The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.

CoreLogic’s Multi-year Alliance with Google Cloud Enables New Product Launch

Retrieved on: 
Monday, August 22, 2022
Commercial Building & Real Estate, Software, Construction & Property, Insurance, Data Analytics, Professional Services, Technology, Residential Building & Real Estate, Cloud, Software, CA, CEO, Technology, Research, CoreLogic, Solution, View, Insurance, Google Cloud, BigQuery, Library, Public sector, Data science, Content discovery platform, Google, Record, Environment, Satellite navigation device

CoreLogic, a leading global property data and analytics-driven solutions provider, has announced an extended relationship with Google Cloud to support the launch of its new CoreLogic Discovery Platform.

Key Points: 
  • CoreLogic, a leading global property data and analytics-driven solutions provider, has announced an extended relationship with Google Cloud to support the launch of its new CoreLogic Discovery Platform.
  • The multi-year relationship between CoreLogic and Google Cloud enables the development of a scalable platform built with several Google Cloud services including Dataproc , BigQuery , Anthos and Cloud Run to manage the data science workloads for predictive and prescriptive analytics.
  • Through the collaboration with Google Cloud, CoreLogics Discovery Platform provides a fully secure and compliant environment with relevant data, tools, security, and governance.
  • Im excited to see our alliance with Google Cloud flourishing, said Patrick Dodd, president and CEO of CoreLogic.

Candel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Retrieved on: 
Friday, August 5, 2022
SIX, ASCO, Trial of the century, GLOBE, American Society of Clinical Oncology, Standard of care, Annual general meeting, Cancer, Clinical trial, Silicon, PD-1, Board, PD-L1, Society, Research, NSCLC, Silicon Valley Bank, Patient, Review, Therapy, Company, Large-cell lung carcinoma, Nivolumab, Doctor of Philosophy, Content discovery platform, CADL, MPH, Board of directors, Insurance, Development, Administration, Pharmaceutical industry, Management, Tutoring, Online gambling, Fellow of the Academy of Medical Sciences, MD, Candel

NEEDHAM, Mass., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.

Key Points: 
  • NEEDHAM, Mass., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.
  • Candel remains on track to achieve several milestones in the second half of 2022, said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel.
  • The Company also plans to debut initial data from its new discovery platform, enLIGHTEN, in the fourth quarter of 2022.
  • Financial Results for the Quarter Ended June 30, 2022
    Cash Position: Cash and cash equivalents as of June 30, 2022 were $86.8 million compared to $82.6 million as of December 31, 2021.

CoreLogic Launches Property Analytics Ecosystem and Data Exchange, Discovery Platform™

Retrieved on: 
Wednesday, June 29, 2022
Commercial Building & Real Estate, Technology, Construction & Property, Insurance, Other Technology, Professional Services, Software, Data Analytics, Data Management, Residential Building & Real Estate, Insurance, Geography, Competition, View, CEO, CoreLogic, Ecosystem, Industry, Seamless, Record, Public sector, Risk, Discovery, Â, Content discovery platform, Time, Data science, Organization, CLIP, Management, Video game console, Online shopping, Risk management

CoreLogic, a leading global property data and analytics-driven solutions provider, has announced the launch of Discovery Platform, a cloud-based data exchange and property analytics ecosystem.

Key Points: 
  • CoreLogic, a leading global property data and analytics-driven solutions provider, has announced the launch of Discovery Platform, a cloud-based data exchange and property analytics ecosystem.
  • Powered by the industrys first integrated property identifier, CoreLogics CLIP ID, and built on more than 50 years of data spanning 99.9% of U.S. properties, Discovery Platform provides a comprehensive property analytics solution.
  • CoreLogics Discovery Platform simplifies this challenge through:
    Seamless data integration: Users can easily integrate their own business objectives and data with CoreLogics data assets.
  • CORELOGIC, the CoreLogic logo, DISCOVERY PLATFORM and CLIP are trademarks of CoreLogic, Inc. and/or its subsidiaries.

Candel Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Retrieved on: 
Wednesday, May 18, 2022
Form, Company, Immunogenic cell death, Private Securities Litigation Reform Act, CADL, Content discovery platform, Nasdaq, Doctor of Philosophy, Patient, HSV, Therapy, Conference, Virus, Technology, SEC, Cancer, MD, GLOBE, Online shopping, Vaccine, Candel, Fellow of the Academy of Medical Sciences

NEEDHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will present an overview of the company at H.C. Wainwrights upcoming Annual Global Investment Conference.

Key Points: 
  • NEEDHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will present an overview of the company at H.C. Wainwrights upcoming Annual Global Investment Conference.
  • To access the webcast recording of the company presentation, please visit the Candel Therapeutics website at https://ir.candeltx.com/news-and-events/events-and-presentations.
  • CAN-2409 is the lead product candidatefrom the adenovirus platform and CAN-3110 is the lead product candidate from the HSV platform.
  • The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.